Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood sugar marker may reveal hidden heart damage after attack

NCT ID NCT07261514

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 674 people who had a severe type of heart attack (STEMI) and were treated with a procedure to open blocked arteries. Researchers checked if a simple blood test called the triglyceride glucose (TyG) index could predict how much heart muscle was damaged and the risk of future problems like another heart attack or heart failure. They found that a higher TyG index was linked to more heart damage and worse outcomes, suggesting this test could help doctors identify high-risk patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

674 people

The number who actually took part.

Started

Jan 2014

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

primary PCI-treated patients with acute STEMI

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\) patients meet diagnostic criteria for STEMI-"The priority for these patients is the implementation of reperfusion therapy as soon as possible .In the appropriate clinical context,ST-segment elevation (accessed at the J-point) indicates possible acute coronary artery in the following situations:New ST elevation at the J-point in at least two contiguous leads:·≥ 2.5 mm in men under 40years,≥2mm in males 40 years and older,or ≥1.5mmin women relatively less of age in leads V2-V3,and/or ≥1mm in the other leads (in the absence of left ventricular hypertrophy or left bundle branch block) Post-STEMI reperfusion with PCI, diagnosis and treatment strategy in accordance with current diagnosis and treatment standards and guidelines27" and complete pPCI within 48h-"" diagnostic strategy meets current diagnostic criteria and guidelines;2) KillIP\<3 and consent to CMR examination and follow-up observation, and CMR examination is completed within 7 days after surgery. 3) Monitor baseline blood glucose and baseline triglycerides during admission. Exclusion criteria: 1) Patients with NSTEMI 2) Lack of clinical data 3) Presence of contraindications to CMR examination-such as implantable cardiac pacemaker, clo gadolinium contrast agent or renal insufficiency; meanwhile, patients with Killip IV cardiac function or clinical instability, and patients with valvular disease, congenital heart disease, pulmonary hypertension, cardiomyopathy history, persistent atrial fibrillation, etc. affecting cardiac structure and function parameters were excluded; Patients with previous history of myocardial infarction, coronary artery intervention and coronary artery bypass grafting were also excluded; patients with severe clinical diseases such as severe hematological diseases, infectious diseases, malignant tumors, liver and kidney failure, and mental disorders or intellectual disabilities who could not cooperate with examination and follow-up; 4) patients with poor MRI quality or sequence deletion were not included in the study. Exclusion Criteria: * Contraindications of CMR examination, such as implantable cardiac pacemaker, claustrophobia, allergy to gadolinium contrast agent or renal insufficiency; meanwhile, patients with Killip IV cardiac function or unstable clinical condition, as well as patients with valve disease, congenital heart disease, pulmonary hypertension, cardiomyopathy history, persistent atrial fibrillation, etc. affecting cardiac structure and function parameters shall be excluded; Patients with a history of myocardial infarction, coronary artery intervention, or coronary artery bypass grafting were also excluded. Patients with severe hematological diseases, infectious diseases, malignant tumors, liver and kidney failure, mental disorders or intellectual disabilities who could not cooperate with examination and follow-up, or poor or missing MRI images were not included in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST elevation (stemi) myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, 100039, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.